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Abstract
Ovarian cancer is a highly lethal disease with poor prognosis and especially in high-grade tumor. Emerging evidence has
reported that aberrant upregulation and activation of GRB7, ERK as well as FOXM1 are closely associated with
aggresivenesss of human cancers. However, the interplay between these factors in the pathogenesis of human cancers still
remains unclear. In this study, we found that GRB7 (P,0.0001), ERK phosphorylation (P,0.0001) and FOXM1 (P= 0.001)
were frequently increased and associated with high-grade tumors, as well as a high tendency in association with advanced
stage ovarian cancer by immunohistochemical analysis. Intriguingly, the expressions of GRB7 (P,0.0001), ERK
phosphorylation (P,0.001) and FOXM1 (P,0.001) showed a significant stepwise increase pattern along Grade 1 to Grade
3 ovarian cancers. Biochemical studies using western blot analysis demonstrated that enforced expression or knockdown of
GRB7 showed GRB7 could elevate the levels of ERK phosphorylation and FOXM1, whereas enforced expression of FOXM1
could not alter levels of GRB7 and ERK phosphorylation. But inhibition of ERK signaling by U0126 or PD98059 could reduce
the level of FOXM1 in GRB7-overexpressing ovarian cancer cells, suggesting that GRB7, ERK and FOXM1 are regulated
orderly. Moreover, inhibition of ERK activity by U0126 or PD98059, or decreased FOXM1 expression by Thiostrepton
significantly inhibited cell migration/invasion, tumor growth in vitro and in vivo. Collectively, our findings confer that
targeting GRB7/ERK/FOXM1 signaling cascade may be a promising molecular therapeutic choice in combating ovarian
cancer.
Citation: Chan DW, Hui WWY, Cai PCH, Liu MX, Yung MMH, et al. (2012) Targeting GRB7/ERK/FOXM1 Signaling Pathway Impairs Aggressiveness of Ovarian
Cancer Cells. PLoS ONE 7(12): e52578. doi:10.1371/journal.pone.0052578
Editor: Muy-Teck Teh, Barts & The London School of Medicine and Dentistry, Queen Mary University of London, United Kingdom
Received August 30, 2012; Accepted November 20, 2012; Published December 20, 2012
Copyright:  2012 Chan et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was supported by the Wong Check She Charitable Foundation. The funder had no role in study design, data collection and analysis, decision
to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: dwchan@hku.hk (DC); hysngan@hku.hk (HN)
Introduction
Ovarian cancer is the most lethal disease among all gynecolog-
ical malignancies [1,2]. The high mortality rate of ovarian cancer
is because of poor prognosis and most cases are detected at late
stage. Ovarian cancer is a heterogeneous tumor exhibiting a wide
range of cytological, clinical and altered genetic features [3,4].
Ovarian high-grade cancers are characterized by high-grade
nuclei, a high mitotic index, more aggressiveness, poorly
differentiated, less responsive to chemotherapy as well as low
survival rate [4,5,6]. The relatively worse pathogenesis and clinico-
pathologic features of high-grade ovarian cancers cause poor
clinical management of this type of disease. Therefore, under-
standing the underlying molecular mechanisms may assist in
developing better curative therapy in aggressive ovarian cancers.
Growth factor receptor-bound protein 7 (GRB7) is a signaling
adaptor which functions to couple signals from cell surface
receptors to specific signaling pathways [7]. Emerging evidences
have reported that GRB7 is overexpressed and usually accompa-
nied with overexpression of erbB2 in human cancers [8,9].
Clinicopathological analyses have shown that the upregulated
GRB7 is associated with metastatic behavior [8,10,11,12]. Besides,
constitutive activation of ERK has been implicated in a variety of
tumorigenic behaviors such as cell proliferation, differentiation,
metastasis, angiogenesis, and chemoresistance in human cancers
[13,14,15,16]. In addition, Forkhead Box M1 (FOXM1) has been
identified as an oncogenic transcription factor which is frequently
upregulated in numerous human cancers [17,18,19]. We and
others have recently found that the upregulation of FOXM1
enhances cell proliferation, migration/invasion and particularly its
expression is involved in cancer progression [17,20,21,22].
Interestingly, the above three factors seem to converge towards
the aggressive cancer properties such as high-grade and advanced
stage tumors, yet the relationship of their regulatory mechanism
has not been completely elucidated. Therefore, the delineation of
the interplay of their regulatory mechanisms will assist in exploring
a potential therapeutic target in ovarian cancer.
In this study, we show that the expressions of GRB7, ERK and
FOXM1 were significantly correlated with the progression of
ovarian cancer. We also describe the regulatory mechanism of
GRB7/ERK/FOXM1 signaling cascade and the inhibition of this
signaling using either the chemical inhibitor U0126 or FOXM1
inhibitor Thiostrepton could remarkably abrogate the ovarian
cancer cell migration/invasion, and in vitro and in vivo tumor
growth. Our results emphasize the importance of the GRB7/
ERK/FOXM1 pathway in tumorigenic properties and argue this
pathway for a promising therapeutic target in high-grade ovarian
cancer.
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Materials and Methods
Cell Lines and Drugs
Two ovarian cancer cell lines: A2780cp (gifts from Prof. BK
Tsang, Dept. of Obstetrics & Gynaecology, University of Ottawa)
[23], and OVCA433 (obtained from American Type Culture
Collection, Rockville, MD), as well as two GRB7 stably expressing
clones; C19 in OVCA433 and C15 in A2780cp which were
generated previously [12] were included in this study. All were
grown at 37uC in 5% CO2 in minimum essential medium or
Dulbecco’s modified Eagle medium supplemented with 10% fetal
bovine serum. MAPK/ERK kinase 1/2 (MEK1/2) inhibitors
PD98059 and U0126, and FOXM1 inhibitor Thiostrepton were
obtained from Calbiochem (La Jolla, CA, USA).
Plasmids and Cell Transfection
The pEGFP/GRB7 expressing plasmids were used as previ-
ously [12]. Four shRNA HuSH 29mer shRNA constructs against
GRB7 in pGFP-V-RS vector were purchased from OriGene
Technologies for generating stable GRB7 knockdown cells (Cat.
No. TG312621, OriGene Technologies, Inc, Rockville, MD,
USA). The non-effective 29-mer scrambled shRNA (TR30013)
(OriGene Technologies) was used as a negative control. To
knockdown human FOXM1, the TriFECTaH RNAi Kit which
contains three siRNAs targeting human FOXM1 was purchased
from IDT (Integrated DNA Technologies, Inc., Iowa, USA). Cell
transfection was carried out using LipofectAMINETM 2000
(Invitrogen) according to the manufacturer’s instructions. The
expression patterns were analyzed by Western blotting. The
parental vector pEGFP-C1 was used as empty vector control.
Figure 1. A significant stepwise increase in the expressions of GRB7, ERK phosphorylation and FOXM1 along ovarian tumor grade.
(A) The expressions of GRB7, ERK phosphorylation and FOXM1 were evaluated by immunohistochemical analysis using specific antibodies on an
ovarian cancer tissue array (OVC1021, Pantomics). (B) Representative pictures show the stepwise increase of GRB7, ERK phosphorylation and FOXM1
expressions from Grade 1 to Grade 3 ovarian cancer (serous subtype) (2006magnifications).
doi:10.1371/journal.pone.0052578.g001
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Immunohistochemical and Western Blot Analyses
Immunohistochemical (IHC) staining for GRB7, ERK phos-
phorylation and FOXM1 was performed on an ovarian cancer
tissue array (OVC1021) (Pantomics Inc, San Francisco, CA) using
primary polyclonal anti-GRB7 (Santa Cruz Biotechnology, Inc.,
Santa Cruz, CA), anti-phospho-ERK (Chemicon International,
Inc., Temecula, USA), and anti-FOXM1 (Abcam, Inc., Cam-
bridge, MA, USA). The percentage of immuno-positive cells in
tumors and normal epithelia was assessed by the proportions of
immuno-positive cells ranged from 10 to 100%, and the intensity
of staining scored as 0 (negative), 1 (faint), 2 (moderate), 3 (strong)
and 4 (marked). The immunoreactivity for each case was scored as
a percentage of the proportions of immuno-positive cells
multiplied by the intensity of staining. The fold change of each
staining was obtained by dividing the expression level of each
cancer sample by the mean immunoreactive staining value of
normal ovaries and borderline mixed cystadenoma. The quanti-
fication of immunohistochemical staining was scored blindly at
least by two independent observers.
For Western blot analysis, cells were lysed with Cell Lysis Buffer
(Cell Signaling Technology, Beverly, MA) containing Protease
Inhibitor Cocktail (Roche, Indianapolis, IN) and PMSF (phenyl-
methylsulphonyl fluoride) (Sigma Chemical Co. St Louise, MO).
The samples were resolved by SDS-PAGE and electroblotted onto
Immobilon-P Transfer Membrane (Millipore Corporation, Bed-
ford, MA). Blots were blocked with 5% skim milk, followed by
incubation with anti-GRB7, FOXM1 (Santa Cruz), GFP (Abcam),
phospho-ERK, ERK (Cell Signaling), and b-actin (Sigma Chem-
ical Co., St Louis, MO). Blots were then incubated with goat anti-
rabbit or anti-mouse secondary antibody conjugate with horse-
radish peroxidase (Amersham Pharmacia Biotech, Cleveland, OH)
and visualized by enhanced chemiluminescence (ECL) (Amer-
sham).
Cell Viability Analysis
Cell viability was measured by Cell Proliferation Kit II (XTT)
for 5 days according to the manufacturer’s instructions (Roche).
The data were collected from at least three independent
experiments.
Cell Migration and Invasion Assays
To quantify the cell migratory and invasive capacities of ovarian
cancer cells, the Transwell cell migration and cell invasion assay
kits (Chemicon International, Inc., Temecula, CA) were used in
this study according to the manufacturer’s instructions. In brief,
1.56105 cells were resuspended in serum free culture medium
(Thiostrepton, PD98059 or U0126 was added when needed) and
seeded on the upper chamber, whereas the full medium was
placed in the lower chamber as chemo-attractant. The plate was
incubated at 37uC and 5% CO2 for 12 hrs for cell migration assay,
Table 1. Clinico-pathological analysis of GRB7, ERK




Parameters n( = 96) #4-fold .4-fold p
phospho-ERK
#4-fold 42 30 (71%) 12 (29%)
.4-fold 54 6 (11%) 48 (89%) ,0.0001*
FOXM1
#2-fold 58 31 (53%) 27 (47%)
.2-fold 38 5 (13%) 33 (87%) ,0.0001*
B
GRB7
Parameters n( = 96) #4-fold .4-fold p
Grade
Low 50 31 (62%) 19 (38%)
High 45 4 (9%) 41 (91%) ,0.0001*
Stage
Early 73 29 (40%) 44 (60%)
Late 23 7 (30%) 16 (70%) 0.469
Metastasis
Yes 23 7 (30%) 16 (70%)
No 73 29 (40%) 44 (60%) 0.469
C
phospho-ERK
Parameters n( = 96) #2-fold .2-fold p
Grade
Low 50 34 (68%) 16 (32%)
High 45 7 (16%) 38 (84%) ,0.0001*
Stage
Early 48 22 (46%) 26 (54%)
Late 48 20 (42%) 28 (58%) 0.837
Metastasis
Yes 23 9 (39%) 14 (61%)
No 73 33 (45%) 40 (55%) 0.639
D
FOXM1
Parameters n( = 96) #2-fold .2-fold p
Grade
Low 50 39 (78%) 11 (22%)
High 45 19 (42%) 26 (58%) 0.001*
Stage
Early 73 45 (62%) 28 (38%)




Parameters n( = 96) #4-fold .4-fold p
Metastasis
Yes 23 13 (57%) 10 (43%)
No 73 45 (62%) 28 (38%) 0.807
doi:10.1371/journal.pone.0052578.t001
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and 48 hrs for cell invasion assay allowing cells to pass through the
pores in the membrane. The cell migrated and invaded rates were
calculated after cell staining and counting by using at least three
different fields for each transwell filter. The experiments were
repeated thrice.
In Vivo Tumorigenicity Assay
To examine the in vivo effects of U0126 and Thiostrepton on
tumor development, 56106 A2780cp cells were inoculated s.c. into
BALB/c nu/nu female mice of 3–4 weeks of age and in groups of
five. The tumor formation in nude mice was monitored for every 3
days. 25 to 50 mmol/kg of U0126 or 200 to 300 mmol/kg
Thiostrepton (Calbiochem, La Jolla, CA, USA) was administered
i.p. once for every 3 days with total of 4 injections into five nude
mice when every tumor size became ,3 mm in diameter. As a
control group, DMSO alone was administrated i.p. for the same
time of treatment. The tumor sizes were measured using slide
calipers and were calculated by the following formula: volume=
(width) 2*length*p/6. The tumor growth curves were plotted from
the mean volume6SEM of tumors from 5 mice. The side effects
such as body weight changes were monitored closely. All the
animal experiments were approved by the University of Hong
Kong Committee on the Use of Live Animals in Teaching and
Research (CULATR No.2560-11).
Statistical Analysis
The clinical parameters were analyzed by SPSS 13.0 software
(SPSS, Chicago, IL). Fisher’s exact test (for parametric data) and
Mann-Whitney test (for non-parametric data) were used to
compare the values between subgroups. The Student’s t-test was
used to analyze the cell viability, migration/invasion and in vivo
tumor growth results. A p-value was considered significant when
less than 0.05.
Figure 2. GRB7/ERK/FOXM1 was regulated in the same signaling axis. (A) Treatment with U0126 (5 mM) showed a significant reduction in
the expression of ERK phosphorylation accompanied with FOXM1 in ovarian cancer cells time dependently, whereas no change in GRB7 expression
was found in A2780cp cells. (B) Treatment of Thiostrepton (20 mM) remarkably reduced the expression of FOXM1 only but no change in the
expressions of GRB7 and ERK phosphorylation in A2780cp cells (left). Depletion of FOXM1 by siRNA knockdown did not alter the expression of GRB7
and ERK phosphorylation (right). C, siRNA scrambled control. si1, si2 and si3 siRNAs targeting three different regions of human FOXM1 and
knockdown the expression of FOXM1 by 60%, 45% and 70% respectively. (C) Two out of four GRB7 shRNA constructs (sh1 and sh2) showed ,70%
knockdown of GRB7 accompanied with a reduction of ERK phosphorylation and FOXM1 expressions in OVCA433 cells. The scrambled control (NC)
was used as negative control. (D) Enforced expression of GRB7 increased ERK phosphorylation and FOXM1. However, treatment with either U0126
(10 mM) or PD98059 (20 mM) could suppress the induced ERK phosphorylation and FOXM1 in A2780cp and OVCA433 ovarian cancer cells.
doi:10.1371/journal.pone.0052578.g002
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Results
GRB7, ERK Phosphorylation and FOXM1 are Frequently
Elevated in Ovarian Cancer
We have previously reported that GRB7 [12], ERK phosphor-
ylation and FOXM1 [21] are overexpressed in ovarian cancer
samples particularly in high-grade tumors. However, the interplay
among these factors in ovarian cancers has not yet been
elucidated. By immunohistochemical (IHC) analysis on an ovarian
cancer tissue array (OVC1021), we found that all of these factors
were congruently upregulated in ovarian cancer samples which
was consistent with our previous findings [12,21]. As expected, the
overexpressed GRB7 (.4 folds) was correlated with the increased
ERK phosphorylation (.2 folds) (P,0.0001, Fisher’s exact test)
and FOXM1 (.3 folds) (P,0.0001, Fisher’s exact test) (Table 1).
In addition, GRB7 (P,0.0001, Fisher’s Exact test), ERK
phosphorylation (P,0.0001, Fisher’s exact test), and FOXM1
(P=0.001, Fisher’s exact test) were significantly correlated with
high-grade tumor and had a high tendency in association with
advanced stage ovarian cancer (GRB7, P=0.021; phospho-ERK,
P=0.065; and FOXM1, P=0.065, Fisher’s exact test) (Table 1). It
was noteworthy that a significant progressive increase of GRB7
(P,0.001, Mann-Whitney’s test), ERK phosphorylation
(P,0.001, Mann-Whitney’s test), and FOXM1 (P,0.001,
Mann-Whitney’s test) expression pattern was observed from
Grade 1 to Grade 3 tumors (Fig. 1A and 1B) and a less obvious
pattern from early to late stage ovarian cancers (Figure S1),
suggesting that these factors play important roles in ovarian cancer
progression. Taken together, these data indicate there is a close
interplay among GRB7, ERK activity and FOXM1 in regulating
ovarian cancer oncogenesis particularly in high-grade tumor.
Figure 3. Inhibition of ERK phosphorylation or FOXM1 significantly decreased both migration and invasion of GRB7-
overexpressing ovarian cancer cells. OVCA433 cells with stable expression of GFP/GRB7 (OVCA433-GRB7) were treated with DMSO as control,
Thiostrepton (20 mM), PD98059 (20 mM) and U0126 (10 mM) for 6 hours and were analyzed by (A) Transwell cell migration assay. The representative
pictures and bar chart showed significant reduction in the number of migratory cells through Matrigel-coated membrane in OVCA433-GRB7 cells
treated with Thiostrepton, PD98059 and U0126 than DMSO control (*P,0.02, Student t-test) at 8-hour; (B) Transwell cell invasion assay. The
representative pictures and bar chart showed significant reduction in the invasion rate in OVCA433-GRB7 cells treated with Thiostrepton, PD98059
and U0126 when compared with DMSO control (*P,0.05, Student t-test) at 15-hour.
doi:10.1371/journal.pone.0052578.g003
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Molecular Regulation of GRB7/ERK/FOXM1 Signaling in
Ovarian Cancer Cells
Given that the increased GRB7, ERK phosphorylation and
FOXM1 significantly correlate with high-grade ovarian tumor,
they may be regulated coordinately in order to mediate
oncogenic functions in ovarian cancer progression. We were
thus interested to investigate the regulatory mechanism amongst
these factors in ovarian cancer cells. For this purpose, both
A2780cp and OVCA433 cells were firstly treated with U0126
MEK1/2 inhibitor. Western blotting showed that ERK phos-
phorylation and FOXM1 were remarkably reduced, but no
change in GRB7 expression was observed (Fig. 2A). Besides,
Figure 4. Inhibition of either ERK phosphorylation or FOXM1 expression impaired cell growth in ovarian cancer cells. (A) XTT cell
proliferation assays showed that the inhibition of ERK phosphorylation by U0126 (10 mM) significantly abrogated the cell proliferation rate in GRB7
stably expressing OVCA433 cells (P=0.020, Student t-test) and A2780cp cells (P= 0.030, Student t-test) as compared with their vector controls. (B) XTT
cell proliferation assays showed that the suppression of FOXM1 expression by Thiostrepton (20 mM) significantly reduced the cell proliferation rate in
GRB7 stably expressing OVCA433 cells (P=0.015, Student t-test) and A2780cp cells (P= 0.025, Student t-test) as compared with their vector controls.
doi:10.1371/journal.pone.0052578.g004
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Figure 5. Inhibition of ERK phosphorylation or FOXM1 expression reduced tumor growth in a mouse xenograft model. (A) The GRB7
stably expressing A2780cp cells (Acp-GRB7) were subcutaneously injected into the right flank of nude mice. Mice were divided into 5 groups (5 mice
per group) and treated with either DMSO as a control, or U0126 (25 or 50 mM/kg) or Thiostrepton (200 or 300 mM/kg) for every 3-day since on day 6
Targeting GRB7/ERK/FOXM1 Signaling Pathway
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treatment of Thiostrepton successfully reduced the level of
FOXM1, while the levels of GRB7 and ERK phosphorylation
were still unchanged (Fig. 2B). To exclude the non-specific
function of Thiostrepton in high-dose treatment, siRNA ap-
proach mediated FOXM1 knockdown was performed in
A2780cp cells. Similar to the treatment of Thiostrepton,
depletion of FOXM1 did not alter the expression of GRB7 and
ERK phosphorylation (Fig. 2B). This indicates that the suppres-
sion of ERK activity could decrease FOXM1 level, whereas the
reduction of FOXM1 expression does not affect either GRB7
expression or ERK activity. To further prove this observation,
stably knockdown of endogenous GRB7 in a GRB7 high
expressing cell line, OVCA433, using shRNA approach clearly
showed that not only GRB7 but also ERK phosphorylation and
FOXM1 were reduced (Fig. 2C). In contrast, enforced expression
of GRB7 increased ERK phosphorylation and FOXM1 in
A2780cp and OVCA433 cells (Fig. 2D). On the other hand,
treatment of either U0126 or PD98059 MEK1/2 inhibitors could
reduce not only ERK phosphorylation but also FOXM1 in
GRB7 ectopic expressing cells (Fig. 2D). Collectively, these
findings confer that GRB7 positively upregulates ERK activity
which in turn elevates FOXM1 in ovarian cancer cells.
Suppression of ERK Activity or FOXM1 Expression
Decreases Ovarian Cancer Cell Migration and Invasion
It has been documented that high-grade ovarian tumor exhibits
high capacity in cell migration/invasion [4,24]. Thus, we
wondered whether inhibition of ERK activity or FOXM1
expression by their specific inhibitors could influence the cell
migration and invasion of ovarian cancer cells. To verify this
hypothesis, a high-grade ovarian cancer cell line, OVCA433,
displaying high migratory and invasive abilities was ectopically
expressed with GFP/GRB7 and treated with inhibitors. Results
showed that treatment of Thiostrepton, PD98059 and U0126
remarkably reduced cell migration rate of OVCA433-GRB7 cells
by 3.5-fold, 2.2-fold and 2.5-fold respectively when compared with
the control (Fig. 3A). Likewise, treatment of Thiostrepton,
PD98059 and U0126 also significantly reduced cell invasion rate
of OVCA433-GRB7 cells by 3.5-fold, 2.6-fold and 2.9-fold
respectively as compared with the control (Fig. 3B). These findings
suggest that the inhibition of GRB7/ERK/FOXM1 signaling is
capable of impairing the cell migration and invasion of ovarian
cancer cells.
Targeting GRB7/ERK/FOXM1 Inhibits Ovarian Cancer
Tumor Growth in vitro and in vivo
Previous studies have shown that constitutive activation of ERK
activity or increased expression of GRB7 and FOXM1 are closely
associated with tumorigenicity of various human cancers
[12,16,21,25,26]. This suggests that targeting any components in
this signaling cascade should theoretically abrogate the tumori-
genic properties in ovarian cancer cells. Indeed, previous
publications reported that knockdown of FOXM1 and ERK
could reduce cell growth and invasiveness of human cancers
[27,28,29]. In this study, we aimed to investigate the tumorigenic
alterations by using pharmaceutical inhibitors specifically targeting
GRB7/ERK/FOXM1 signaling cascade. We thus firstly evaluat-
ed the suppressive effect on cell proliferation of two high-grade
serous ovarian cancer cell lines; A2780cp and OVCA433 using
U0126 (10 mM). By XTT cell proliferation assay, both A2780cp
(P=0.02, Student t-test) and OVCA433 (P=0.03, Student t-test)
exhibited significant reduction in cell proliferation rate as
compared with their controls (Fig. 4A). Similarly, upon treatment
of Thiostrepton (20 mM), A2780cp (P=0.015, Student t-test) and
OVCA433 (P=0.025, Student t-test) also showed a profound
reduction in cell proliferation rate as compared with their controls
(Fig. 4B).
We next examined the in vivo tumorigenic activity of GRB7 in
A2780cp by subcutaneously inoculation GRB7 and vector control
expressing A2780cp cells into one flank of nude mice. As expected,
GRB7 stably expressing A2780cp cells exhibited 30% faster tumor
growth as compared with the vector control (P=0.020, Student t-
test) (Figure S2). We next investigated the suppressive effect on
tumor growth of GRB7 stably expressing A2780cp upon treatment
of U0126 or Thiostrepton. When the tumor size reached ,3 mm
in diameter in tumor bearing nude mice on Day 6, U0126 at 25
and 50 mM/kg was i.p. injected into peritoneal cavity of nude mice
for every 3-day. After 4 times of U0126 injection, we found that
there were 35% and 72% reductions in tumor size as compared
with DMSO control on Day 18 when injected with U0126 at
25 mM/kg (P=0.032, Student t-test) and 50 mM/kg (P=0.005,
Student t-test) respectively (Figure 5A and 5B). Besides, upon
treatment of Thiostrepton for 200 mM/kg and 300 mM/kg on Day
9, there were 47% and 52% reduction in tumor growth as
compared with DMSO control on Day 18 respectively (P,0.01,
Student t-test) (Figure 5A and 5B). These findings highlight that
the upregulation of GRB7 could enhance tumor growth, while
using either U0126 or Thiostrepton could efficiently reduce the
tumor growth of ovarian cancer cells both in vitro and in vivo.
Discussion
In this study, we present evidence that GRB7, ERK phosphor-
ylation and FOXM1 are increased in ovarian cancer. Interesting-
ly, the concomitant increase of GRB7, ERK phosphorylation and
FOXM1 is associated with high-grade ovarian cancers. Impor-
tantly, we show that these factors are coordinately regulated in
GRB7/ERK/FOXM1 signaling axis in ovarian cancer cells.
Functionally, inhibiting ERK activity by U0126 or PD98059 and
FOXM1 expression by Thiostrepton remarkably inhibit ovarian
cancer cell migration/invasion and tumor growth in vitro and
in vivo. These findings clearly evidence that the activated GRB7/
ERK/FOXM1 signaling cascade plays an important role in the
pathogenesis of high-grade ovarian cancer.
Constitutive activation of ERK signaling pathway has been
involved in human cancer development [30,31,32]. Indeed,
targeting this pathway to combat human cancers has been
attracted plenty of effort to develop effective drugs for the past
decade [15,33,34,35]. We and others have recently found that
GRB7 and its variant, GRB7v, are frequently upregulated in
ovarian cancers and are able to enhance cell proliferation,
migration/invasion through activating ERK signaling pathway
[12,36,37]. On the other aspect, emerging evidences have found
that the aberrant upregulation of FOXM1 transcription factor is
involved in the pathogenesis of various human cancers
[17,21,22,38,39]. Although all of these aberrantly activated factors
(Arrows represent the injections). The relative tumor size was calculated relative to those of the first day of treatment (day 0) and are represented as
relative mean size (%)6SE for each group (*P= 0. 032, **P,0.01, and ***P= 0. 005, are significantly different from the DMSO control group, Student t-
test). (B) The representative pictures and bar charts show the average tumor weight of each group taken on day 18. (*P= 0. 043, **P=0. 001, and
***P,0.02, are significantly different from the DMSO control group, Student t-test).
doi:10.1371/journal.pone.0052578.g005
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are dominantly associated with cancer pathogenesis, there is no
report so far to mention the signaling link amongst GRB7, ERK
activity and FOXM1 in human cancer cells. In this study, by using
IHC analysis of ovarian cancer tissue array, we show that GRB7,
ERK phosphorylation and FOXM1 are concomitantly increased
in ovarian cancer samples. Intriguingly, their expressions exhibit a
stepwise increase along the tumor grade of ovarian cancers. In
fact, our clinicopathological correlation analysis provides further
evidence that their upregulated expressions are significantly
associated with high-grade tumor. As we know, this is the first
report showing the expression status of these factors involved in
the progression of ovarian cancers thus far. All in all, these findings
indicate that GRB7, ERK phosphorylation and FOXM1 form an
oncogenic convergence in high-grade ovarian cancer pathogene-
sis. Therefore, targeting this signaling cascade may achieve a good
outcome when treating this type of disease.
GRB7 is a known adaptor which relays signals from cell surface
receptors to specific downstream signaling cascades via the
protein-protein interaction of its Src-homology 2 (SH2) domain
to a variety of tyrosine kinases [7,40,41]. We and others have
previously reported that GRB7 is frequently overexpressed and
promotes cell proliferation, cell migration and cell invasion of
human cancers [10,12,42]. Given to its important roles as signal
transduction molecules in activating oncogenic signaling pathways,
numerous studies have attempted to develop inhibitors targeting to
the SH2 domain of GRB7 in order to inhibiting aberrant
activation of related signaling activities and eliminating cancer
cells [43,44,45,46]. For examples, the combination of Grb7 cyclic
peptide, G7-18NATE, with chemo-drugs were capable of
inhibiting breast cancer cell growth [47,48], or with the specific
peptide ligand to suppress GRB7-mediated metastasis in pancre-
atic carcinoma etc [11,49]. However, the specificity and affinity
are the main hurdles encountered in the development of these
inhibitors as GRB7-targeted molecular therapeutics [26,49,50].
Here, our data show that GRB7 regulates ERK activity and the
FOXM1 expression orderly and is in agreement with our previous
reports [12,21], indicating that the overexpressed GRB7 enhances
ovarian cancer cell growth and cell migration/invasion through
elevating ERK and FOXM1 activities. Therefore, we proposed
that suppressing the aberrant activated ERK and FOXM1 should
exert similar effects of using GRB7 inhibitor in inhibiting the
above tumorigenic properties of ovarian cancer cells. Indeed, our
in vitro and in vivo tumorigenic studies clearly show that the ovarian
cancer cell growth and cell migration/invasion are remarkably
reduced upon treatments of PD98059 or U01260, and Thios-
trepton via targeting MEK/ERK and FOXM1 activities respec-
tively. More importantly, the tumor suppressive effects derived
from either U0126/PD98059 or Thiostrepton are equivalent.
These findings seem to provide an alternative approach when
developing GRB7-targeted therapeutics in ovarian cancer.
In summary, this study shows that aberrant activation of
GRB7/ERK/FOXM1 signaling cascade is significantly correlated
with the development of ovarian cancer. Targeting this signaling
axis by MEK/ERK or FOXM1 inhibitors could obtain promising
effect on the signal transduction-based therapy for this disease.
Supporting Information
Figure S1 Immunohistochemical analysis showed in-
creased expressions of GRB7, ERK phosphorylation and
FOXM1 were associated with advanced stage ovarian
cancers.
(TIF)
Figure S2 Enforced expression of GRB7 increases
tumor growth in mouse xenograft model. The GRB7
stably expressing A2780cp cells (Acp-GRB7) and empty vector
control A2780cp cells (Acp-V) were subcutaneously injected into
the right flank of nude mice (5 mice per group). The tumor size
was monitored for every 3-day. The representative pictures and
bar charts show the average tumor weight of each group taken on
day 18. (*P=0.02, Student t-test).
(TIF)
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